27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) closed up 39.6 percent Thursday and continued another 3.9 percent pre-market Friday — but not on its own merits.
The stock moved mostly on sympathy for SAGE Therapeutics Inc (NASDAQ:SAGE), a biotech peer that released positive clinical data on its brexanolone treatment for major depressive disorder and subsequently surged 70 percent.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Street analysts expect the drug to advance to Phase 3 studies, eventually secure regulatory approval and potentially prove efficacious in treating Parkinson’s and essential tremor.
Sage’s progress was well interpreted by Marinus investors, who back a similar pipeline to treat postpartum depression and epilepsy. Marinus’ ganaxolone, a GABA modulator akin to SAGE-217, is in Phase 2 development for four separate trials.
At the time of publication, Marinus shares were set to open up 2.4 percent at $8.85, while Sage was up 1.7 percent at $158.99.
Related Links:
Hertz Moving In Sympathy With Avis Budget
5 Dry Bulk Shipping Stocks Moving In Sympathy With Diana Containerships Outsized Move
Hasbro, Mattel Just Proved That Sympathy Plays Don't Always Pay Off
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.